AC Immune SA operates as a clinical-stage biopharmaceutical enterprise dedicated to discovering, designing, and developing innovative precision medicines and diagnostics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and related neurodegenerative conditions. The company utilizes proprietary technology platforms—such as SupraAntigen and Morphomer—to generate targeted immunotherapies and small-molecule treatments designed to prevent or modify the pathological spreading of disease-associated proteins in the human brain. Its primary mission is to transform patient care by delivering disease-modifying interventions developed through rigorous scientific research and strategic pharmaceutical collaborations.